drugset / Trial / NCT01509547

Varenicline for Adolescent Smoking Cessation

NCT01509547

Phase 3 Completed 157 enrolled Medical University of South Carolina
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo.

Timeline

Start
2012-08
Primary completion
2018-01-26
Completion
2018-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 0.5 mg
Subject Varenicline Small molecule 1 mg

Indications